T of 24 clients (4 people acquired two doses) with significant bleeding, none of whom was struggling haemophilia. The typical patient age was forty nine.5 years (array 24?seven), and typical overall body mass was 70.four kg (variety 55?20). The subsequent illnesses ended up diagnosed: most cancers ?6 sufferers (liver most cancers, two individuals; ovarian cancer, two individuals; prostate, 1 affected individual; kidney, just one affected person), post-abdominal medical procedures bleeding ?four people, ruptured belly aorta aneurysms ?three patients, sepsis ?3 individuals, acute pancreatitis ?two individuals, postkidney transplant troubles ?two people, postpartum bleeding ?two people, GI bleeding ?two sufferers. Among the list of described patients with sepsis was a girl dealt with with drotreocogin (Xigris, Lilly) infusion. The common dose of rFVIIa was 22.fifty three /kg (vary ten?six). The normal blood reduction inside twelve several hours in advance of procedure was 2728 ml and the typical blood reduction within just 12 hours following PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/6800653 procedure was 184 ml. The normal dynamics of bleeding before therapy was 1163 ml/hours compared to 184 ml/hours following therapy. The dissimilarities in between the volumeP165 Efficacy of recombinant activated variable VII from the management of critical hemorrhage adhering to cardiac surgeryN Trecova, I Dementjeva, V Gladisheva Russian Investigation Centre DOTATATE of Surgical procedures RAMS, Moscow, Russian Federation Important Care 2006, 10(Suppl one):P165 (doi:ten.1186/cc4512) Introduction Critical bleeding immediately after cardiac surgical procedures is often complicated to manage. The efficacy of regular prescription drugs vary, that is why it can be essential to use more recent brokers for helpful handle and prevention of massive bleeding. The intention of this study is scientific analysis in the efficacy of recombinant activated aspect VII (rFVIIa) during the treatment method of bleeding in the course of and just after cardiac surgical treatment by stimulation of clot formation within the site of injuries. Individuals and strategies rFVIIa (NovoSeven? Novo Nordisk, Bagsvaerd, Denmark) was used in 37 grownup people aged in between forty nine and sixty eight several years who underwent open up coronary heart operation (10 sufferers coronary PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/6104837 surgical procedure, five patients valvular surgical treatment, six patients surgical treatment of congenital coronary heart defects, three sufferers operation of dilated cardiomyopathy) or surgical procedure for aortic aneurisms (thirteen patients) in 2002?005. All individuals had normal coagulation parameters before surgical procedure. In these people, bleeding (ten?0 ml/min) has developed intraoperatively or postoperatively. In 21 sufferers the bleeding started off following surgical treatment intraoperatively, as well as in 16 sufferers severe hemorrhage designed while in the postoperative interval. Remedy of bleeding provided infusions of fresh frozen plasma, platelet focus, aprotinin and ?aminocaproic acid. Two people underwent surgical re-exploration for bleeding. Nonetheless pharmacological and surgical administration unsuccessful to stop the hemorrhage. Just before administration of rFVIIa, blood reduction achieved 2.5? l in some sufferers. rFVIIa was administered in doses of 60?0 /kg overall body body weight. We applied Student's t exam for statistical analysis the laboratory info before and following rFVIIa. Success Right after administration in the first median dose (seventy five.three ?10.1 ) rFVIIa bleeding stopped in 27 patients (74 ), and markedly decreased in four individuals in the course of one hour. 6 clients who didn't advantage from first rFVIIa administration acquired more drug in doses of 70?0 /kg, with excellent benefits in four clients. (5 patients been given one supplemental dose, one affected individual obtained 4 doses.)Desk one (abstract P165) Variable Prothrombin time (s) Thrombin time (s) APTT (s) ACT (s) Platel.